Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abicipar pegol in Exudative AMD
NCT01397409Phase 2Completed
- Sponsor
- Allergan
- Start
- Sep 2011
- Primary completion
- Mar 2014
- Modality
- Carrier/Scaffold Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of abicipar pegol in exudative age-related macular degeneration, sponsored by Allergan. Started Sep 2011; status: completed.
02
Drugs
abicipar pegol
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01397409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397409.